Cytokinetics, Inc. (NASDAQ:CYTK) insider Caryn Gordon Mcdowell sold 2,709 shares of Cytokinetics stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $9.00, for a total value of $24,381.00. Following the completion of the sale, the insider now directly owns 15,077 shares of the company’s stock, valued at approximately $135,693. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Caryn Gordon Mcdowell also recently made the following trade(s):

  • On Thursday, November 2nd, Caryn Gordon Mcdowell sold 4,260 shares of Cytokinetics stock. The stock was sold at an average price of $12.94, for a total value of $55,124.40.

Cytokinetics, Inc. (NASDAQ CYTK) traded up $0.67 during mid-day trading on Friday, reaching $9.47. The company’s stock had a trading volume of 228,444 shares, compared to its average volume of 301,033. The company has a quick ratio of 7.60, a current ratio of 7.60 and a debt-to-equity ratio of 0.14. The stock has a market cap of $507.86, a price-to-earnings ratio of -5.71 and a beta of 1.61. Cytokinetics, Inc. has a 1-year low of $7.00 and a 1-year high of $17.20.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.64) by $0.04. The business had revenue of $6.18 million during the quarter, compared to analyst estimates of $5.35 million. Cytokinetics had a negative return on equity of 62.64% and a negative net margin of 172.27%. sell-side analysts expect that Cytokinetics, Inc. will post -2.4 EPS for the current fiscal year.

CYTK has been the subject of several recent research reports. Cantor Fitzgerald reissued a “buy” rating and issued a $21.00 price objective on shares of Cytokinetics in a report on Tuesday, September 26th. Seaport Global Securities reissued a “buy” rating and issued a $24.00 price objective on shares of Cytokinetics in a report on Friday, October 6th. Morgan Stanley reissued an “overweight” rating and issued a $25.00 price objective (up previously from $24.00) on shares of Cytokinetics in a report on Friday, October 6th. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of Cytokinetics in a report on Friday, October 27th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Cytokinetics in a report on Sunday, October 29th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. Cytokinetics presently has an average rating of “Buy” and an average target price of $17.91.

A number of hedge funds have recently bought and sold shares of the business. Fox Run Management L.L.C. purchased a new position in Cytokinetics during the 4th quarter valued at about $181,000. Wasatch Advisors Inc. grew its holdings in Cytokinetics by 139.1% during the 4th quarter. Wasatch Advisors Inc. now owns 1,679,778 shares of the biopharmaceutical company’s stock valued at $13,690,000 after buying an additional 977,106 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Cytokinetics during the 3rd quarter valued at about $187,000. Piedmont Investment Advisors LLC purchased a new position in Cytokinetics during the 3rd quarter valued at about $159,000. Finally, Janus Henderson Group PLC grew its holdings in Cytokinetics by 3.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,778,605 shares of the biopharmaceutical company’s stock valued at $40,290,000 after buying an additional 93,675 shares in the last quarter. 73.61% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Caryn Gordon Mcdowell Sells 2,709 Shares of Cytokinetics, Inc. (CYTK) Stock” was published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2018/01/19/caryn-gordon-mcdowell-sells-2709-shares-of-cytokinetics-inc-cytk-stock.html.

Cytokinetics Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.